Semax: A Deep Rodent Record, a BDNF Signal, and an Eastern European Approval

The short version

Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) built from two components: ACTH(4-7), a fragment of the stress hormone ACTH that lacks cortisol-releasing activity, and a C-terminal Pro-Gly-Pro tail added to slow enzymatic breakdown. The name of the game is BDNF and NGF — the brain's own growth and maintenance factors. In rats, a single 50 microgram-per-kilogram intranasal dose raises BDNF mRNA in the hippocampus and brainstem within hours ^[3], and raises BDNF protein specifically in the basal forebrain ^[4]. In ischemia models it reduces cortical infarct volume and preserves memory performance ^[5].

Here is the honest framing. Nearly all mechanistic and efficacy work is in rodents. The clinical evidence base comes almost entirely from Russian and Ukrainian studies conducted in patients with stroke, cognitive impairment and optic-nerve disease — registered uses as a prescription drug in those countries. There are no FDA- or EMA-approved indications and no published Western randomized controlled trials. In the United States, Semax is sold as an unscheduled research chemical, not a pharmaceutical product. This page reports what the research shows; it is not advice and lists no human dose.

What it is

Semax is a synthetic linear heptapeptide with the one-letter sequence MEHFPGP. The first four residues (Met-Glu-His-Phe) correspond to the ACTH(4-7) segment of adrenocorticotropic hormone — a portion that retains the neuropeptide's behavioral activity but lacks its steroidogenic (cortisol-driving) function. The appended Pro-Gly-Pro tripeptide is an engineering choice: it slows enzymatic degradation and extends the biological window of the intact peptide in the body, though pharmacokinetic data in rats show the intact heptapeptide still breaks down within minutes ^[6].

It is commonly supplied as an acetate salt and, in Russian clinical practice, as an intranasal spray formulation. Outside Russia and Ukraine, it has no approved pharmaceutical form; material sold as Semax in most markets is research-grade, with variable purity and no required quality standard.

How it works

Semax's best-characterized mechanism is neurotrophin upregulation. In male Wistar rats given a single 50 microg/kg intranasal dose, mRNA levels of NGF and BDNF rose in the hippocampus and BDNF mRNA rose in the brainstem and cerebellum within hours — while NGF mRNA fell in frontal cortex, indicating the regulation is gene- and region-specific, not a global boost ^[3]. Separately, a binding study in rat basal-forebrain membranes identified a specific, reversible, calcium-dependent binding site with a dissociation constant of 2.4 nM and confirmed a rapid, region-specific rise in BDNF protein in the basal forebrain (but not the cerebellum) three hours after dosing ^[4].

A second mechanism involves enkephalin-degrading enzyme inhibition. In human serum in vitro, Semax inhibited neprilysin-type peptidases that normally degrade the endogenous opioid enkephalin, with an IC50 of approximately 10 micromolar — more potently than several reference compounds ^[7]. This is proposed to extend the calming and analgesic effects of endogenous opioid signaling, though the in-vivo relevance at intranasal doses has not been directly demonstrated.

In ischemia models, a genome-wide transcriptomic analysis of permanent MCAO in rats found that Semax's neuroprotective effect was dominated by shifts in immune-system gene expression (immunoglobulins and chemokines, over 50% of affected genes) and vascular-system gene expression, rather than by a simple receptor-ligand action ^[2]. The picture is of a peptide that orchestrates a broad biological response in injured brain rather than hitting a single target.

Pharmacokinetically, a radiolabeled study in rats found ~0.093% of the administered dose per gram appeared in brain within two minutes of intranasal dosing, with ~80% as intact Semax at that early time point and the remainder as metabolites, followed by rapid enzymatic breakdown ^[6]. Brain entry is fast; residence of the intact peptide is brief.

What the research shows

Neuroprotection in spinal cord injury. In female C57BL/6 mice with T9-T10 spinal-cord injury, Semax improved locomotor recovery scores (Basso, inclined-plane, footprint measures) and reduced pyroptosis via an Oprm1/USP18/FTO signaling axis — a 2025 study identifying a mu-opioid-receptor-gene pathway as part of the mechanism ^[1].

Ischemia and memory. Intranasal Semax given for six days in a rat model of focal photoinduced prefrontal-cortex ischemia decreased cortical infarct volume and improved retention of a conditioned passive-avoidance response, indicating both a structural neuroprotective effect and an antiamnesic behavioral benefit ^[5].

Neurotrophin biology. Region-specific rapid changes in NGF and BDNF gene expression at 50 microg/kg ^[3] and a specific reversible binding site (KD 2.4 nM) with corresponding BDNF protein rise in the basal forebrain ^[4] are among the best-characterized molecular findings and inform the nootropic rationale for Semax.

Enzyme inhibition in human serum. The IC50 of ~10 micromolar for enkephalin-degrading enzymes in human serum in vitro ^[7] is the closest thing to human molecular data in the corpus; it does not constitute a clinical finding.

Immune and vascular gene shifts in ischemic brain. Genome-wide analysis in permanent MCAO rats showed more than 50% of Semax-modulated genes were immune-related, with additional vascular gene shifts — framing neuroprotection as an immunomodulatory and vascular-regulatory effect rather than a simple receptor action ^[2].

Reported effects, cautions & safety

Community-reported effects (anecdotal, not clinical evidence). The nootropic research community describes Semax in terms that map, loosely, onto the BDNF and enkephalinase science. The most consistent self-report is a quiet onset of mental clarity within the first hour — organized thinking, reduced mental fog — without the wired, stimulant-like quality of caffeine. Sustained focus, improved verbal fluency, a modest mood lift and, for a meaningful minority, essentially no perceptible effect are all frequently mentioned. The effect is widely described as lasting a few hours before fading, consistent with the peptide's rapid clearance ^[6]. These are subjective reports from nootropic forums and biohacker communities, not measured outcomes.

Adverse effects reported by the same communities include nasal burning or stinging on intranasal administration (very common; typically resolves in fifteen minutes), afternoon fatigue or sleepiness as the effect wears off (occasional), irritability or overstimulation — more likely when stacked with stimulants — (minority), and headache (occasional). Vivid dreams or disrupted sleep when dosed late in the day are a minority report.

Cited safety cautions. Several cautions follow directly from the mechanistic literature:

• Unregulated sourcing. In the US, Semax is a research chemical with no required purity, identity, or sterility testing. Published pharmacology was not conducted on consumer product ^[6].
• Limited independent human safety data. Human evidence is largely Russian-language clinical studies in stroke and cognitive-impairment patients under medical supervision; there are no Western RCTs. Long-term safety in healthy people using it as a nootropic is not characterized in independent literature.
• Neurotrophin and gene-expression scope. Rapidly changing BDNF, NGF and large numbers of immune and vascular genes ^[3][2] is not a trivial pharmacological nudge. Consequences of repeated neurotrophin driving in a healthy human brain over months are unstudied.
• Drug interaction unknowns. Because Semax raises serotonin metabolites, potentiates amphetamine-evoked dopamine in rodents, and inhibits enkephalin-degrading enzymes ^[7], combination with stimulants, serotonergic antidepressants or opioid-active drugs carries unstudied additive-effect risk.
• No established human dosing framework. All quantitative data are from animal studies in micrograms per kilogram; no validated human dosing schedule outside Russian clinical formulations exists.

Where it fits

Among the three peptides on this desk, Semax has the deepest mechanistic rodent file and the most studied neuroprotective story — BDNF/NGF upregulation, enkephalinase inhibition, and broad transcriptomic shifts in injured brain. Its clinical record is geographically narrow (Russian and Ukrainian practice) and its human data outside that context essentially absent. Read alongside Selank, which approaches the nootropic question through the anxiety and GABA axis, and DSIP, which targets sleep architecture, Semax illustrates the general pattern: a coherent, decades-deep preclinical signal that has not been independently replicated in Western controlled trials. See the comparison page for a structured side-by-side.